

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported):** December 17, 2024 (December 11, 2024)

**Arrowhead Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-38042  
(Commission  
File Number)

46-0408024  
(IRS Employer  
Identification No.)

177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105  
(Address of principal executive offices, including Zip Code)

**Registrant's telephone number, including area code :** (626) 304-3400

**Not applicable  
(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ARWR	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 11, 2024, Douglass Given, M.D., Ph.D. tendered his retirement from the Board of Directors (the “Board”) of Arrowhead Pharmaceuticals, Inc. (the “Company”), effective as of December 31, 2024. Dr. Given has served on the Board for fourteen years and currently serves as the Chairman of the Board and as a member of the Science Committee. The Company wishes to thank Dr. Given for his years of service on the Board.

The Company expects that Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, Inc. (“Sarepta”), will join the Board in the first calendar quarter of 2025 concurrent with the closing under the Company’s Exclusive License and Collaboration Agreement with Sarepta, dated as of November 25, 2024.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 17, 2024

ARROWHEAD PHARMACEUTICALS, INC.

By:                     /s/ Kenneth Myszkowski  
                    Kenneth Myszkowski  
                    Chief Financial Officer